| Literature DB >> 25781897 |
Fei Wang1, Xiaojuan Wang1, Xiaolan Yu1, Ling Fu, Lin Fu1, Yunyun Liu1, Lixin Ma1, Chao Zhai1.
Abstract
Endo-β-Entities:
Mesh:
Substances:
Year: 2015 PMID: 25781897 PMCID: PMC4362766 DOI: 10.1371/journal.pone.0120458
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Primers used for overlapping PCR in this study.
| Primers | Oligonucleotide Sequences (5'→3') |
|---|---|
| EndoH-1 |
|
| EndoH-2 |
|
| EndoH-3 |
|
| EndoH-4 |
|
| EndoH-5 |
|
| EndoH-6 |
|
| EndoH-7 |
|
| EndoH-8 |
|
| EndoH-9 |
|
| EndoH-10 |
|
| EndoH-11 |
|
| EndoH-12 |
|
| EndoH-13 |
|
| EndoH-14 |
|
| EndoH-15 |
|
| EndoH-16 |
|
| EndoH-17 |
|
| EndoH-18 |
|
| EndoH-19 |
|
| EndoH-20 |
|
| EndoH-21 |
|
| EndoH-22 |
|
| EndoH-23 |
|
| EndoH-24 |
|
| EndoH-25 |
|
| EndoH-26 |
|
Note: The underlined EndoH-1 and EndoH-26 sequences matched the sticky ends generated by CpoI and NotI, respectively.
Fig 1The alignments of Endo H-P with wild-type Endo H.
The nucleotide sequence of Endo H-P was compared with that of wild-type Endo H, the result indicated that 220 nucleotides were altered in Endo H-P.
Fig 2Whole-cell PCR to identify the recombinant P. pastoris bearing Endo H-P ORF.
M DNA molecular weight markers (the size of each band was indicated on the left);Lane 1–6 PCR using 6 transformants as the templates; Lane 7 PCR with pHBM-Endo H-P plasmid as the template (positive control); Lane 8 PCR using P. pastoris bearing pHBM905A plasmid as the template (negative control).
Fig 3SDS-PAGE analysis of Endo H-P secreted in the cell culture supernatant of the shake flasks.
M protein molecular weight marker (the size of each band was indicated on the left); Lane 1 cell culture supernatant (15 μl) of the strain bearing pHBM905A plasmid (negative control); Lane 2–7 cell culture supernatants (15 μl) collected from 1 to 6 days, respectively.
Fig 4Determining the enzyme activity of Endo H-P through mobility shift assay of RNase B.
M protein molecular weight markers (the size of each band was indicated on the left); Lane 1 denatured RNase B (negative control); Lane 2 denatured RNase B treated with 1 U of commercial Endo H from NEB, USA (positive control); Lane 3–8 denatured RNase B treated with 1μl of Endo H-P diluted into 5.0%, 4.0%, 3.5%, 3.0%, 2.5% and 2.0%, respectively.
Fig 5The hydrolytic activity of Endo H-P to proteins from mammals and baker's yeast.
(A). The hydrolytic activity of Endo H-P to EPO expressed in CHO cells. Lane 1 EPO without treatment; Lane 2 EPO treated with commercial Endo H; Lane 3 EPO treated with purified Endo H-P; Lane 4 EPO treated with commercial PNGase F. (B). The hydrolytic activity of Endo H-P to CPY from baker's yeast. Lane 1 CPY without treatment; Lane 2 CPY treated with commercial Endo H; Lane 3 CPY treated with purified Endo H-P.
Fig 6Analyzing the characteristics of Endo H-P through mobility shift assay of RNase B.
(A).Identifying the optimum temperature of Endo H-P with SDS-PAGE. M protein molecular weight markers (the size of each band was indicated on the left);Lane 1 to Lane 6 denatured RNase B treated with concentrated Endo H-P at 25°C, 30°C, 35°C, 40°C, 45°C and 50°C, respectively; Lane 7 denatured RNase B treated with concentrated Endo H-P at 37°C, respectively;Lane 8 the negative control (RNase B without treatment); Lane 9 the positive control (overdose of Endo H-P was added to the reaction system);(B). Identifying the optimum temperature of Endo H-P with SDS-PAGE. M protein molecular weight markers (the size of each band was indicated on the left);Lane 1 the positive control (overdose of Endo H-P was added to the reaction system); Lane 2 the negative control (RNase B without treatment);Lane 3–8 denatured RNase B treated with Endo H-P at pH5.0, 5.5, 6.0, 6.5, 7.0 and 7.5, respectively.
Fig 7Deglycosylation of recombinant proteins expressed in P. pastoris.
(A). SDS-PAGE of the recombinant proteins expressed in P. pastoris with or without digestion of Endo H-P with post-fermentation method. M protein molecular weight markers (the size of each band was indicated on the left); Lane 1 positive control(Horseradish Peroxidase) from the Glycoprotein Staining Kit;Lane 2 negative control(Soybean Trypsin Inhibitor) from Glycoprotein Staining Kit;Lane 3 mannosidase expressed in P. pastoris;Lane 4 deglycosylated mannosidase; Lane 5 phytase expressed in P. pastoris; Lane 6 deglycosylated phytase;Lane 7 DpnI expressed in P. pastoris;Lane 8 deglycosylated DpnI. (B). Glycoprotein staining of the recombinant proteins expressed in P. pastoris with or without Endo H-P digestion. All samples were loaded in the identical order with A.
Fig 8Co-fermentaion of EndoH-P with the recombiant DNase I and phytase.
M protein molecular weight markers (the size of each band was indicated on the left); Lane 1 phytase expressed in P. pastoris; Lane 2 phytase co-induced with Endo H-P in P. pastoris; Lane 3 DNase I expressed in P. pastoris; Lane 4 DNase I co-induced with Endo H-P in P. pastoris; Lane 5 Endo H-P expressed in P. pastoris.
Fig 9Co-fermentaion the phytase expressing P. pastoris and Endo H-P expressing P. pastoris with various initial ratio of cells innoculated in BMMY medium.
M protein molecular weight markers (the size of each band was indicated on the left); Lane 1 phytase expressed in P. pastoris; Lane 2–8 EndoH-P-expressing P. pastoris co-fermentated with phytase-expressing P. pastoris with inoculation ratio of 1:10, 1:25, 1:50, 1:100, 1:200, 1:500 and 1:1000 (Endo H-P: phytase), respectively.
Fig 10The growth curves of phytase expressing P. pastoris with or without co-fermentation with Endo H-P expressing P. pastoris.
(A).The growth curve of phytase- and Endo H-P-expressing P. pastoris during the vegetative growth phase. (B). The growth curve of phytase- and Endo H-P- expressing P. pastoris during the induction phase. The names of the strains were indicated at the bottom of the panel.
Fig 11Analysis of the enzymatic activity of deglycosylated DNase I and endo-1, 4-β-mannosidase obtained from co- and post-fermentation with Endo H-P.
(A). M DNA molecular weight markers (the size of each band was indicated on the left); Lane 1 pHBM905A plasmid (about 300 ng); Lane 2 pHBM905A treated with 1 μl supernatant of DNase I; Lane 3–4 pHBM905A treated with 0.5 and 1 μl of deglycosylated DNase I with post-fermentation treatment; Lane 5 pHBM905A treated with 1 U commercial DNase I; Lane 6–7 pHBM905A treated with 0.5 and 1 μl of deglycosylated DNase I with co-fermentation treatment; Lane 8 pHBM905A treated with fermentation supernatant from P. pastoris bearing pHM905A plasmid (the negative control). (B). A hole of about 2mm was made with a hole puncher on a MD plate supplemented with 1% konjac powder and 0.05% trypan blue. The samples were added into the wells and the plate was incubated at 37°C, overnight. Sample 1: 1.5 μl supernatant of P. pastoris expressing glycosylated endo-1, 4-β-mannosidase; Sample 2: 2 μl supernatant of P. pastoris expressing glycosylated mannanase; Sample 3: 2 μl supernatant of deglycosylated endo-1, 4-β-mannosidase with post-fermentation treatment; Sample 4: 2 μl supernatant of deglycosylated endo-1, 4-β-mannosidase with co-fermentation treatment; Sample 5: 2 μl supernatant of EndoH-P.